Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB) Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
In vitro evaluation of Isoxyl, a mycolic acid inhibitor in combination with rifampicin and Isoniazide against mycobacteria other than M. tuberculosis Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
The emerging problem of treating pulmonary M. avium complex (MAC) disease – microbial substitution of MAC to M. abscessus , Scedosporium and Nocardia after multi-drug chemotherapy in pulmonary MAC disease Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009
Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012
Validation of the MGIT 960 technique for 2nd line drug susceptibility testing (DST) of Mycobacterium tuberculosis Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Regional reference centre for multi-drug resistant tuberculosis – 11 months of activity Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Detection of M. tuberculosis multi-drug resistance using GenoType® MTBDRplus Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
Drug resistance of Mycobacterium tuberculosis to fluoroquinolones (Q) Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Artificial pneumothorax in the treatment of multi drug resistant tuberculosis (MDR TB) Source: Eur Respir J 2006; 28: Suppl. 50, 586s Year: 2006
Express diagnostics of mycobacterium tuberculosis (MBT) drug resistance at disseminated tuberculosis (DT) Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives Year: 2008
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Molecular fingerprinting of mycobacterium tuberculosis isolates in new cases of tuberculosis using mycobacterial interspersed repetitive unit–variable number tandem repeat genotyping (MIRU-VNTR) – Epidemiology of drug resistant tuberculosis in Greece Source: Annual Congress 2010 - Clinical tuberculosis Year: 2010
Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005